Therapeutics and Clinical Risk Management
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Enzyme replacement therapy for Fabry disease: some answers but more questions
(6734) Total Article Views
Authors: Majid Alfadhel, Sandra Sirrs
Published Date February 2011
Volume 2011:7 Pages 69 - 82
Majid Alfadhel1, Sandra Sirrs2
1Division of Biochemical Diseases, Department of Paediatrics, BC Children’s and Women’s Hospital, University of British Columbia, Vancouver, BC, Canada; 2Adult Metabolic Diseases Clinic, Division of Endocrinology, Department of Medicine, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada
Abstract: Fabry disease (FD) is a multisystem, X-linked disorder of glycosphingolipid metabolism caused by enzyme deficiency of α-galactosidase A. Affected patients have symptoms including acroparesthesias, angiokeratomas, and hypohidrosis. More serious manifestations include debilitating pain and gastrointestinal symptoms, proteinuria and gradual deterioration of renal function leading to end-stage renal disease, hypertrophic cardiomyopathy, and stroke. Heterozygous females may have symptoms as severe as males with the classic phenotype. Before 2001, treatment of patients with FD was supportive. The successful development of enzyme replacement therapy (ERT) has been a great advancement in the treatment of patients with FD and can stabilize renal function and cardiac size, as well as improve pain and quality of life of patients with FD. In this review, we have provided a critical appraisal of the literature on the effects of ERT for FD. This analysis shows that data available on the treatment of FD are often derived from studies which are not controlled, rely on surrogate markers, and are of insufficient power to detect differences on hard clinical endpoints. Further studies of higher quality are needed to answer the questions that remain concerning the efficacy of ERT for FD.
Keywords: Fabry disease, agalsidase α, agalsidase β, Replagal, Fabrazyme, critical appraisal, evidence-based medicine
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS) is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- Cancer Pharmacogenomics and Targeted Therapies
17 - 19 September, 2014
- ESMO 2014 Congress
26 - 30 September, 2014
- ACG Annual Scientific Meeting
17 - 22 October, 2014
Pennsylvania Convention Center, Philadelphia
- 27th ECNP Congress
18 - 21 October, 2014
- ISPOR 17th Annual European Congress 2014
8 - 12 November, 2014
Amsterdam, The Netherlands
- 26th EORTC-NCI-AACR SYMPOSIUM 2014
18 - 21 November, 2014
- Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
- Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss